Sunshine Biopharma's Adva-27a Featured in 2014 Worldwide Uterine Cancer Report for Its Effectiveness Against Multidrug Resist...
June 09 2014 - 8:00AM
Marketwired
Sunshine Biopharma's Adva-27a Featured in 2014 Worldwide Uterine
Cancer Report for Its Effectiveness Against Multidrug Resistant
Uterine Cancer Cells
MONTREAL, QUEBEC--(Marketwired - Jun 9, 2014) - Sunshine
Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on
the research, development and commercialization of drugs for the
treatment of various forms of cancer, today announced that
Adva-27a, the Company's flagship oncology drug candidate was
featured in Global Markets Direct: Uterine Cancer - Pipeline
Review, H1 2014 Report for its effectiveness against multidrug
resistant uterine cancer cells in vitro.
The Global Markets Direct Uterine Cancer Report provides
comprehensive information on the therapeutic development for
Uterine Cancer, with comparative analysis, therapeutics assessment,
mechanism of action, route of administration and molecule
type. The Report also reviews key players involved in the
therapeutic development for Uterine Cancer including Sunshine
Biopharma Inc.
In December 2012, Sunshine Biopharma announced that it had
achieved dramatic effects in Uterine Cancer using its Adva-27a
compound. The studies were carried out in MES-SA/Dx5, a
Uterine Sarcoma cell line that has become multidrug resistant
through the use of a commonly administered chemotherapy drug,
Doxorubicin. Adva-27a was able to efficiently kill these cells
with an IC50 of less than 8 micromolar, a pharmacologically very
favorable drug concentration.
In addition to Uterine Cancer, Adva-27a has been shown to be
effective at killing multidrug resistant Breast Cancer cells,
Small-Cell Lung Cancer cells and Pancreatic Cancer cells (Published
in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October
2012).
Sunshine Biopharma recently reported that it has initiated the
construction of mouse xenograft models for Pancreatic Cancer as
part of the plans of positioning Adva-27a for clinical development
for Pancreatic Cancer in parallel with the previously announced
multidrug resistant Breast Cancer indication. The first U.S.
patent covering Adva-27a was issued on August 7, 2012 under U.S.
patent number 8,236,935.
"We are very pleased that this testing indicated that our drug,
Adva-27a, is effective against Uterine Cancer," said Dr. Steve N.
Slilaty, CEO of Sunshine Biopharma. "In the U.S. alone, over
52,000 new cases of Uterine Cancer are diagnosed each
year. "We are anxious to begin our clinical studies soon and
look forward to the opportunity of providing a new treatment for
Uterine Cancer patients worldwide," he added.
About The Global Markets Direct: Uterine Cancer - Pipeline
Review, H1 2014 Report
The following links provide more information about the Global
Markets Direct: Uterine Cancer - Pipeline Review, H1 2014:
http://www.globalmarketsdirect.com/Report.aspx?ID=Uterine-Cancer-Pipeline-Review-H1-2014&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
http://www.researchandmarkets.com/research/9bk98l/uterinecancer
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a
small molecule that has recently been shown to be effective at
killing multidrug resistant Breast Cancer cells, Small-Cell Lung
Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells
(Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432,
October 2012). Adva-27a is currently in the IND-Enabling stage
of development. The original U.S. patent covering Adva-27a was
issued on August 7, 2012 under U.S. patent number
8,236,935. The Company is planning a Phase I clinical trial of
Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical
trial of Adva-27a for multidrug resistant Breast Cancer to be
conducted at McGill University's Jewish General Hospital in
Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, including statements as to revenue
projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
future collaboration agreements, the success of the Company's
development, events conditioned on stockholder or other approval,
or otherwise as to future events, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.
For Additional Information Contact: Camille Sebaaly, CFO
Sunshine Biopharma Inc. Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com www.sunshinebiopharma.com